
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 13G

**Under the Securities Exchange Act of 1934
(Amendment No. 4)***

Nabriva Therapeutics PLC
(Name of Issuer)

Ordinary Shares, nominal value €0.01 per share
(Title of class of securities)

62957M104
(CUSIP number)

June 28, 2019
(Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Name of Reporting Person: Novo Holdings A/S
2.	Check the Appropriate Box if a Member of Group (See Instructions): (a) <input type="checkbox"/> (b) <input type="checkbox"/>
3.	SEC Use Only:
4.	Citizenship or Place of Organization: Denmark
Number of Shares Beneficially Owned By Each Reporting Person With:	5. Sole Voting Power: 3,446,564
	6. Shared Voting Power: 0
	7. Sole Dispositive Power: 3,446,564
	8. Shared Dispositive Power: 0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person: 3,446,564
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares: <input type="checkbox"/>
11.	Percent of Class Represented By Amount In Row (9): 4.74% (1)
12.	Type of Reporting Person: CO

(1) Based upon 72,782,466 Ordinary Shares outstanding as of June 6, 2019, as reported in the Issuer's Proxy Statement filed with the Securities and Exchange Commission (the "SEC") on June 14, 2019.

This Amendment No. 4 amends the Schedule 13G/A filed with the SEC on February 8, 2017.

- Item 1.**
- (a) **Name of Issuer:**
Nabriva Therapeutics PLC
 - (b) **Address of Issuer's Principal Executive Offices:**
Leberstrasse 20
1110 Vienna, Austria
- Item 2.**
- (a) **Name of Person Filing:**
Novo Holdings A/S, a Danish limited liability company, is wholly owned by Novo Nordisk Fonden (the "Foundation"), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S, Novozymes A/S and NNIT A/S) and is responsible for managing the Foundation's assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.
 - (b) **Address or Principal Business Office or, if none, Residence:**
Tuborg Havnevej 19
2900 Hellerup, Denmark
 - (c) **Citizenship or Place of Organization:**
Novo Holdings A/S: Denmark
 - (d) **Title of Class of Securities:**
Ordinary Shares
 - (e) **CUSIP Number:**
62957M104
- Item 3.** **If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**
Not applicable.

Item 4. Ownership:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:	3,446,564 (1)
(b) Percent of class:	4.74% (2)
(c) Number of shares as to which such person has:	
(i) Sole power to vote or to direct the vote:	3,446,564 (1)
(ii) Shared power to vote or to direct the vote:	0
(iii) Sole power to dispose or to direct the disposition of:	3,446,564 (1)
(iv) Shared power to dispose or to direct the disposition of:	0

- (1) Novo Holdings A/S, through its Board of Directors (the “Novo Board”), has the sole power to vote and dispose of the shares (or ADS) beneficially owned by Novo Holdings A/S (the “Novo Shares”). The Novo Board, currently comprised of Lars Rebien Sorensen, Steen Riisgaard, Francis Cuss, Jean-Luc Butel, Jeppe Christiansen and Vivian Monges, may exercise voting and dispositive control over the Novo Shares only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Novo Shares.
- (2) Based upon 72,782,466 Ordinary Shares outstanding as of June 6, 2019, as reported in the Issuer’s Proxy Statement filed with the SEC on June 14, 2019.

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following .

Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 1, 2019

Novo Holdings A/S

/s/ Peter Haahr

By: Peter Haahr

Its: Chief Financial Officer

Signature Page to Schedule 13G/A
Reporting Person: Novo Holdings A/S Issuer: Nabriva Therapeutics PLC